IDEXX delivered robust financial results in Q2 2025, driven by strong growth in Companion Animal Group diagnostics and record instrument placements. EPS rose 49% as reported, while international growth outpaced domestic gains.
Revenue reached $1.11 billion, up 11% year-over-year
EPS increased 49% to $3.63, including discrete tax benefits
Net income rose to $293.99 million for the quarter
Record placements of IDEXX inVue Dxâ„¢ instruments fueled capital revenue growth
IDEXX raised full-year 2025 guidance across revenue, EPS, and operating margin due to strong Q2 results and favorable foreign exchange impacts.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance